Does Pretransplant C-Peptide Influence Outcomes Following Simultaneous Pancreas-Kidney Transplantation: A Case-Control Study
Abdominal Transplant Surgery, Wake Forest Baptist Health, Winston Salem, NC
Meeting: 2020 American Transplant Congress
Abstract number: A-303
Keywords: Kidney/pancreas transplantation, Pancreas, Pancreas transplantation, Peptides
Session Information
Session Name: Poster Session A: Biomarkers, Immune Assessment and Clinical Outcomes
Session Type: Poster Session
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
Location: Virtual
*Purpose: The study purpose was to evaluate outcomes in SPKT pts according to presence or absence of pretransplant Cp
*Methods: Selection criteria for Cp positive (Cp+, ≥2.0 ng/ml) pts were similar to Cp negative (Cp-) pts. We retrospectively analyzed 215 SPKTs performed at our center between 8/02 – 3/19 and identified 41 in pts who were Cp+ pretransplant (mean level 5.4 ng/ml) who were compared to 41 Cp- (level undetectable) case controls matched for recipient age, gender, race, and date of transplant. All SPKTs were performed as intent to treat with portal-enteric drainage; all pts received depleting antibody induction with FK/MMF ± steroids. Pancreas graft loss (GL) was defined as return to daily insulin therapy
*Results: The two groups were well matched for numerous donor, preservation, recipient, and immunological characteristics. Mean donor (26 Cp+ vs 23 yrs Cp-) and recipient (both 44 yrs) ages were similar. Both groups had 21 males/20 females and 19 Caucasian (C)/20 African American (AA) pts. There was one early death secondary to infection in each group. There were no other early (<6 month) kidney graft losses (GL) in either group. There were 5 other early pancreas GLs, 3 in Cp+ and 2 in Cp- pts. With a mean follow-up of 88 months in both groups, 5-year patient survival (PS, 93% vs 95%), kidney graft survival (GS, 73% vs 85%), and pancreas GS (68% vs 85%, p=0.11) rates were slightly lower in Cp+ vs Cp- pts, respectively. Death-censored kidney (69% vs 73%) and pancreas GS (59% vs 81%, p=0.07) rates were also slightly lower in Cp+ vs Cp- pts, respectively. The Cp+ group had fewer deaths with functioning grafts (9.8% vs 19.5% Cp) but more pancreas GLs (9.8% vs 0 Cp-, p=0.12) due to either insulin resistance (in pts with normal C-p levels and excessive weight gain) or rejection (19.5% vs 12% Cp-, p=NS). There were no differences in outcomes according to gender or race. Post-transplant weight gain >3 kg occurred in 76% of Cp+ vs 32% of Cp- pts (p=.0001). Mean post-transplant weight gain was 15 kg in Cp+ vs 6.5 kg in Cp- pts (p<.001). In pts with functioning grafts, mean post-transplant Cp (4.9 vs 2.6 ng/ml), HbA1c (5.5 vs 5.2%) and serum creatinine (1.4 vs 1.2 mg/dl) levels were slightly higher in Cp+ pts whereas mean eGFR levels (61 vs 66 ml/min/1.73 m2) were slightly lower compared to Cp- pts
*Conclusions: In this case-control study, survival and functional outcomes in Cp+ pts are slightly inferior following SPKT, with post-transplant weight gain and GL due to insulin resistance or rejection accounting for differences in outcomes.
To cite this abstract in AMA style:
Gurram V, Gurung K, Rogers J, Farney A, Orlando G, Jay C, Reeves-Daniel A, Mena-Gutierrez A, Sakhovskaya N, Doares W, Kaczmorski S, Gautreaux M, Stratta R. Does Pretransplant C-Peptide Influence Outcomes Following Simultaneous Pancreas-Kidney Transplantation: A Case-Control Study [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/does-pretransplant-c-peptide-influence-outcomes-following-simultaneous-pancreas-kidney-transplantation-a-case-control-study/. Accessed November 25, 2024.« Back to 2020 American Transplant Congress